Volume 21, Number 8—August 2015
Research
Differentiation of Acute Q Fever from Other Infections in Patients Presenting to Hospitals, the Netherlands1
Stephan P. Keijmel
, Elmer Krijger, Corine E. Delsing, Tom Sprong, Marrigje H. Nabuurs-Franssen, and Chantal P. Bleeker-Rovers
, Elmer Krijger, Corine E. Delsing, Tom Sprong, Marrigje H. Nabuurs-Franssen, and Chantal P. Bleeker-Rovers
Table 6
Initial treatment for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*
| Initial treatment | Study group, n = 82, no. positive/no. tested (%) | Control group, n = 52, no. positive/no. tested (%) | p value† |
|---|---|---|---|
| Doxycycline | 29/82 (35) | 8/52 (15) | 0.001 |
| Moxifloxacin | 5/82 (6) | 2/52 (4) | NS |
| Ciprofloxacin | 7/82 (9) | 6/52 (12) | NS |
| Penicillin | 7/82 (9) | 1/52 (2) | 0.049 |
| Amoxicillin | 13/82 (16) | 5/52 (10) | NS |
| Amoxicillin/clavulanic acid | 3/82 (4) | 4/52 (8) | NS |
| Piperacillin/tazobactam | 1/82 (1) | 5/52 (10) | NS |
| Cephalosporin | 14/82 (17) | 17/52 (33) | NS |
| Co-trimoxazole | 0/82 (0) | 1/52 (2) | NS |
| Flucloxacillin | 2/82 (2) | 0/52 (0) | NS |
| Clarithromycin | 0/82 (0) | 1/52 (2) | NS |
| No treatment | 1/82 (1) | 1/52 (2) | NS |
| Unknown | 0/82 (0) | 1/52 (2) | NS |
| Patients with adequate treatment‡ | 34/74 (46) | NA | NA |
*NS, not significant; NA, not applicable.
†By χ2 test.
‡Defined as use of doxycycline (200 mg/d), moxifloxacin (400 mg 1×/d), or ciprofloxacin (500 mg 2×/d) for >2 wk.
1Preliminary results from this study were presented as a poster (P1851) at the 22th annual European Congress of Clinical Microbiology and Infectious Diseases, March 31–April 3, 2012, London, UK.
Page created: July 14, 2015
Page updated: July 14, 2015
Page reviewed: July 14, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.